In breast cancer patients with a high recurrence score, the 5-year disease-free rate was significantly higher for patients receiving taxanes with anthracycline and cyclophosphamide than for those ...

GO-PIMs are prevalent in patients with cancer treated in a national health care system, with increasing GO-PIMs independently linked to frailty and worse clinical outcomes,” the researchers wrote.

Enhanced staffing and flexible resource allocation were key in managing patient surge after Oct. 7, 2023, attack in Southern Israel.

Researchers present an overview of treatment and management strategies for patients with HR+/HER2+ breast cancer, including common adverse effects.